FDA Quality Assurance Unit
Center for Drug Evaluation & Research quality assurance head James Bilstad, MD, will retire from the agency effective Dec. 31. Bilstad, previously director of CDER's Office of Drug Evaluation II, moved to the QA unit in April, due to potential conflicts of interest following the appointment of his wife, Cheryl Graham, MD, as VP-U.S. regulatory affairs at Pfizer (1"The Pink Sheet" April 26, p. 4) Bilstad joined the agency in 1974
You may also be interested in...
FDA Pulmonary Drug Products Division Director John Jenkins, MD, has been selected to head FDA's Office of Drug Evaluation II, beginning April 25.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials